PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.
Why Is PerkinElmer (PKI) Up 7% Since Last Earnings Report?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up
by Zacks Equity Research
Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.
PerkinElmer (PKI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 5.81% and 1.38%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy PerkinElmer (PKI) Ahead of Earnings?
by Zacks Equity Research
PerkinElmer (PKI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?
by Zacks Equity Research
Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.
Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?
by Zacks Equity Research
DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) continued focus on research and development and strategic buyouts are likely to drive Q2 results.
What's in Store for Cerner (CERN) This Earnings Season?
by Zacks Equity Research
Cerner's (CERN) Q2 results are likely to show softer performance owing to declining revenues across core business segments.
What's in Store for AmerisourceBergen (ABC) in Q3 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q3 results are likely to be driven by its core Pharmaceutical Distribution business; a competitive industry is a headwind.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.
Can Business Services Aid athenahealth's (ATHN) Q2 Earnings?
by Zacks Equity Research
athenahealth's (ATHN) core Business Services unit is likely to drive growth in Q2; the company's focus on cloud-based services is encouraging.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q2 Earnings?
by Zacks Equity Research
Strong performance in the Diagnostics Segment is likely to drive PerkinElmer's (PKI) Q2 results. The segment fortifies the company's market position in terms of exclusiveness of services.
Zacks Industry Outlook Highlights: Waters, Mettler-Toledo and PerkinElmer
by Zacks Equity Research
Zacks Industry Outlook Highlights: Waters, Mettler-Toledo and PerkinElmer
Instruments - Scientific Outlook: Growth Prospects Abound
by Aniruddha Ganguly
Instruments - Scientific industry's growth prospect is quite bright in the near term given rising spending by the government and academic labs.
Here's Why You Should Invest in PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) gains from stellar Q1 performance; a raised guidance holds promise.
PerkinElmer (PKI) Q1 Earnings & Revenues Top, '18 View Up
by Zacks Equity Research
Solid prospects in PerkinElmer's (PKI) DAS segment are the key drivers of Q1. Strength in life sciences end markets, informatics profile and OneSource have given the top line a boost.
Is a Surprise Coming for PerkinElmer (PKI) This Earnings Season?
by Zacks Equity Research
PerkinElmer (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q1 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) gains from EUROIMMUN buyout, solid guidance buoys optimism.
DENTSPLY to Acquire OraMetrix, Boost CAD-CAM Dental Unit
by Zacks Equity Research
The acquisition of OraMetrix is likely to bolster DENTSPLY's (XRAY) dental business.
Here's Why You Should Invest in athenaheath Stock Right Now
by Zacks Equity Research
athenahealth's (ATHN) strong product portfolio is likely to expand its customer base in the coming quarters.
Luminex (LMNX) Product Portfolio Solid, Competition Rife
by Zacks Equity Research
Luminex's (LMNX) flagship VERIGENE and ARIES systems are likely to boost its growth trajectory.
3 Reasons Why You Should Invest in Fresenius Medical Now
by Zacks Equity Research
Wide range of dialysis products, deliberate initiatives to gain market traction and solid international foothold are major catalysts for Fresenius Medical (FMS) at the moment.
Favorable Market Trend & Core Business Expansion Aid STERIS
by Zacks Equity Research
STERIS' (STE) string of six buyouts in fiscal 2018 keeps us upbeat about the stock. The same is expected to strengthen its Healthcare Specialty Services and Applied Sterilization Technologies arms.